narsoplimab — CRL

“On October 18, 2021, the Company issued a press release announcing the receipt of a complete response letter from the U.S. Food and Drug Administration (the "FDA") regarding the Company's Biologics License Application ("BLA") for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy ("HSCT-TMA").”